Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ileal bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating patients with progressive familial intrahepatic cholestasis, as well as for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis. It has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. The company is headquartered in Boston, Massachusetts.
IPO Year: 2007
Exchange: NASDAQ
Website: albireopharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/9/2023 | $53.00 → $42.00 | Outperform → Neutral | Wedbush |
| 9/8/2022 | $55.00 | Buy | Guggenheim |
| 3/28/2022 | $75.00 | Outperform | Wedbush |
| 11/5/2021 | $79.00 → $80.00 | Buy | HC Wainwright & Co. |
| 9/16/2021 | $82.00 → $84.00 | Outperform | Wedbush |
| 7/21/2021 | $73.00 → $82.00 | Outperform | Wedbush |
Submission status for ALBIREO PHARMA INC's drug BYLVAY (ORIG-1) with active ingredient ODEVIXIBAT has changed to 'Approval' on 07/20/2021. Application Category: NDA, Application Number: 215498, Application Classification: Type 1 - New Molecular Entity